Leiden – – October 06, 2026 -- Qurin has launched the Qatra Genomic DNA Extraction Lab Kit (RUO), a Research Use Only product capable of processing urine volumes up to 400 mL, a full void, compared with the 40-50 mL standard in conventional laboratory workflows.
Qatra kit delivers 7.6-fold increase in DNA yield in internal studies
In internal studies, average DNA yields rose 7.6-fold as sample volume increased from 50 mL to 400 mL. Qurin states this volume expansion could allow researchers to recover substantially more biomarker material from a single sample, particularly relevant when target DNA is present at low concentrations.
Proprietary bead chemistry replaces multi-step extraction workflows
The kit relies on a patent-pending magnetic bead surface chemistry for DNA capture from whole urine, paired with a patent-pending magnetic retrieval system designed to recover DNA-loaded beads from large sample volumes in a single workflow. This removes the need to concentrate or split large urine samples across multiple extraction runs, a common requirement in existing protocols. The workflow has been built with automation compatibility in mind, supporting scalable processing for laboratory settings.
Qatra kit is the first product from Qurin's broader R&D platform
The gDNA extraction kit marks the first commercial output of Qurin's Qatra R&D Program, which targets capture and extraction technologies for multiple biomarker classes from urine, including cell-free DNA, RNA, extracellular vesicles, and proteins. The company is developing bead-based modules for laboratory use and cartridge-based modules for at-home collection, aiming for a modular platform architecture.
Marc Peeters, CEO at Qurin, said the company's aim is to process more of the available urine and recover more of its molecular information while making the process efficient and scalable.
Company cites renal filtration pathway for tumor-derived DNA detection
Qurin notes that circulating cell-free DNA, including tumor-derived fragments, can cross the renal filtration barrier and enter urine, extending the matrix's potential relevance beyond urogenital cancers. The Qatra kit is designated for Research Use Only and is not intended for diagnostic procedures.